BeOne Medicines Ltd (HK:6160)
:6160
Want to see HK:6160 full AI Analyst Report?
Top Page
BeOne Medicines Ltd
(6160)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$208.00
â–²(7.66% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by improved financial performance, including a clear profitability inflection and strong positive free cash flow. Technical indicators are mildly supportive but not strongly trending versus longer-term averages. Valuation is the main constraint due to a relatively high P/E and no provided dividend yield support.
Positive Factors
High and Sustainable Margins
An ~87% gross margin and ~12% EBIT margin indicate durable product-level pricing power and efficient cost structure. Such margins support reinvestment in R&D and commercial expansion, and provide a structural buffer against cyclical revenue swings, aiding long-term profitability.
Negative Factors
Slowing Revenue Growth
A shift from earlier hyper-growth to ~7% TTM growth indicates the company is moving into a steadier growth phase. Structurally, this raises the bar for sustaining investor expectations and increases dependence on product lifecycle management, new approvals, and international expansion to drive long-term top-line gains.
Read all positive and negative factors
Positive Factors
Negative Factors
High and Sustainable Margins
An ~87% gross margin and ~12% EBIT margin indicate durable product-level pricing power and efficient cost structure. Such margins support reinvestment in R&D and commercial expansion, and provide a structural buffer against cyclical revenue swings, aiding long-term profitability.
Read all positive factors
BeOne Medicines Ltd (6160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$273.94B
Dividend YieldN/A
Average Volume (3M)5.08M
Price to Earnings (P/E)34.8
Beta (1Y)0.93
Revenue Growth37.65%
EPS GrowthN/A
CountryHK
Employees11,000
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.37
Shares Outstanding1,426,363,900
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$253.58Price Target Upside31.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)3.94
Revenue Forecast (FY)HK$50.69B
BeOne Medicines Ltd Business Overview & Revenue Model
Company Description
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler o...
How the Company Makes Money
null...
BeOne Medicines Ltd Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 21, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong performance by BeOne, with significant revenue growth driven by BRUKINSA's market leadership and robust R&D advancements. However, challenges remain due to aggressive competition and potential regulatory impacts. Overall, the positive aspects significantly outweigh the challenges.Positive Updates
Significant Revenue Growth
BeOne's revenue reached $1.3 billion, representing a 42% year-on-year growth.
Negative Updates
Competition and Pricing Challenges
Despite strong market position, competition aggressively discounting in the BTK market.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
BeOne's revenue reached $1.3 billion, representing a 42% year-on-year growth.
Read all positive updates
Company Guidance
During the Q2 2025 earnings call for BeOne Medicines, the company provided strong financial guidance and updates on their strategic priorities. The company reported a revenue of $1.3 billion for the second quarter, marking a 42% year-over-year increase. BRUKINSA, the leading BTK inhibitor in the U.S. market, contributed $950 million to the global revenue, showcasing a 49% year-over-year growth. The company's gross margin improved to approximately 87%, attributed to favorable product mix and production cost efficiencies. The financial guidance for the full fiscal year 2025 was updated, with total revenue expectations ranging between $5 billion and $5.3 billion. The operating expenses are projected to remain between $4.1 billion and $4.4 billion, with a commitment to achieving positive GAAP operating income and generating positive free cash flow. The company also highlighted several upcoming R&D milestones, including global filings and pivotal data readouts for their key pipeline assets. Overall, BeOne Medicines emphasized their robust execution, strong market positioning, and continued focus on innovation and growth across their oncology portfolio.BeOne Medicines Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.73B | 5.35B | 3.81B | 2.46B | 1.42B | 1.18B |
| Gross Profit | 5.00B | 4.56B | 3.22B | 2.08B | -511.06M | -447.86M |
| EBITDA | 834.90M | 589.69M | -396.44M | -1.12B | -1.72B | -1.39B |
| Net Income | 512.28M | 287.36M | -644.79M | -881.71M | -2.00B | -1.46B |
Balance Sheet | ||||||
| Total Assets | 8.56B | 8.23B | 5.92B | 5.81B | 6.38B | 8.65B |
| Cash, Cash Equivalents and Short-Term Investments | 4.83B | 4.59B | 2.63B | 3.17B | 4.53B | 6.62B |
| Total Debt | 2.05B | 1.09B | 1.08B | 930.18M | 596.67M | 694.64M |
| Total Liabilities | 3.77B | 3.84B | 2.59B | 2.27B | 2.00B | 2.40B |
| Stockholders Equity | 4.76B | 4.36B | 3.33B | 3.54B | 4.38B | 6.24B |
Cash Flow | ||||||
| Free Cash Flow | 1.10B | 943.13M | -669.77M | -1.75B | -1.97B | -1.61B |
| Operating Cash Flow | 1.29B | 1.13B | -140.63M | -1.16B | -1.50B | -1.30B |
| Investing Cash Flow | -199.91M | -276.56M | -548.35M | 60.00M | 1.08B | 640.66M |
| Financing Cash Flow | 1.16B | 1.06B | 193.45M | 416.48M | -18.97M | 3.64B |
BeOne Medicines Ltd Technical Analysis
Positive
193.20
Price Trends
180.53
Positive
189.66
Negative
191.91
Negative
Market Momentum
-0.50
Positive
52.19
Neutral
46.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6160, the sentiment is Positive. The current price of 193.2 is above the 20-day moving average (MA) of 181.95, above the 50-day MA of 180.53, and above the 200-day MA of 191.91, indicating a neutral trend. The MACD of -0.50 indicates Positive momentum. The RSI at 52.19 is Neutral, neither overbought nor oversold. The STOCH value of 46.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6160.
BeOne Medicines Ltd Risk Analysis
BeOne Medicines Ltd disclosed 93 risk factors in its most recent earnings report. BeOne Medicines Ltd reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BeOne Medicines Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | HK$355.88B | 16.25 | 28.07% | 1.84% | 19.90% | 86.59% | |
72 Outperform | HK$206.79B | 34.88 | 16.59% | 0.97% | 22.62% | 26.23% | |
68 Neutral | HK$273.94B | 34.81 | 12.04% | ― | 37.65% | ― | |
64 Neutral | HK$135.98B | 24.33 | 10.55% | ― | 16.79% | 47.14% | |
64 Neutral | HK$143.49B | 145.72 | 4.82% | ― | 38.55% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6160
BeOne Medicines Ltd
184.50
38.80
26.63%
HK:1801
Innovent Biologics
80.95
22.35
38.14%
HK:2269
Wuxi Biologics (Cayman)
32.72
8.87
37.19%
HK:2359
WuXi AppTec Co., Ltd. Class H
130.00
63.46
95.36%
HK:3692
Hansoh Pharmaceutical Group Company Limited
33.72
8.35
32.91%
HK:1276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
61.35
6.39
11.63%
BeOne Medicines Ltd Corporate Events
BeOne Medicines Files U.S. Shelf Registration to Expand Capital Market Access
May 6, 2026
BeOne Medicines Ltd. has filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission, enabling it to offer securities on a delayed or continuous basis in the U.S. market. The filing, which qualifies as a large ac...
BeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access
May 6, 2026
BeOne Medicines Ltd. has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission, enabling it to offer securities on a delayed or continuous basis in the U.S. market. The move underscores the Swiss-based, ...
BeOne Medicines Issues Q1 2026 Unaudited Results and Cautious Guidance
May 6, 2026
BeOne Medicines Ltd., a Switzerland-based oncology-focused biopharmaceutical company listed in Hong Kong, develops cancer therapies including combination regimens and potential first-in-class treatments for blood cancers such as chronic lymphocyti...
BeOne Medicines Highlights Global Footprint With Latest Form 10-Q Filing
May 6, 2026
BeOne Medicines Ltd. has released its quarterly report on Form 10-Q for the period ended March 31, 2026, which was filed with the U.S. Securities and Exchange Commission and simultaneously announced in Hong Kong under the exchange’s overseas...
BeOne Medicines Posts U.S. Proxy Materials, Highlights Cross-Border Disclosure
Apr 28, 2026
BeOne Medicines Ltd. has issued an overseas regulatory announcement in Hong Kong to notify investors of the internet availability of its proxy materials, which have also been filed with the U.S. Securities and Exchange Commission as definitive add...
BeOne Medicines Sets 2026 AGM and Moves to Web-First Proxy Distribution
Apr 28, 2026
BeOne Medicines Ltd. has convened its 2026 annual general meeting of shareholders for June 11, 2026, in Zurich, setting May 22, 2026, as the record date for eligibility to vote. The company, which is listed in the U.S., Hong Kong and Shanghai, is ...
BeOne Medicines Sets Record Date for 2026 AGM to Define Voting Rights
Apr 28, 2026
BeOne Medicines has set May 22, 2026, as the record date to determine shareholders entitled to attend and vote at its 2026 annual general meeting, requiring share transfer documents to be lodged with its Hong Kong branch registrar by 4:30 p.m. tha...
BeOne Medicines Sets May 6 Date for First‑Quarter 2026 Results and Investor Call
Apr 22, 2026
BeOne Medicines Ltd. said it will publish its unaudited financial results for the first quarter ended March 31, 2026, after Hong Kong trading hours on May 6, 2026, with the figures prepared under U.S. GAAP and reviewed and approved by the board...
BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM
Apr 16, 2026
BeOne Medicines Ltd. has nominated ten directors for election at its 2026 annual general meeting, including three new candidates: Dr. Felix J. Baker as a non-executive director, and Elizabeth F. Mooney and Dr. Charles L. Sawyers as independent non...
BeOne Medicines Grants RSUs to 154 Employees Under 2016 Incentive Plan
Apr 8, 2026
BeOne Medicines has granted 17,678 restricted share units, equivalent to 229,814 underlying shares or about 0.01% of its issued share capital, to 154 employees under its 2016 Share Option and Incentive Plan. The awards, which require no considerat...
BeOne Medicines Swings to Profit on 40% Revenue Surge in 2025
Mar 25, 2026
BeOne Medicines Ltd. reported a strong turnaround for the year ended December 31, 2025, as total revenues rose 40.2% year-on-year to about US$5.3 billion, driven almost entirely by product revenue growth of roughly US$1.5 billion. The surge in sal...
BeOne Medicines Updates HKEX Waivers and Compliance Disclosures
Mar 13, 2026
BeOne Medicines has published an updated company information sheet dated March 13, 2026, detailing its current waivers and exemptions from certain provisions of the Hong Kong Listing Rules and related ordinances. The board affirms responsibility f...
BeOne Medicines Updates on Employee Share Purchase Plan Uptake
Mar 12, 2026
BeOne Medicines has reported the outcome of the latest offering period under its Fifth Amended and Restated 2018 Employee Share Purchase Plan, which allows eligible staff to buy shares, including ADSs, at a 15% discount funded through payroll dedu...
BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules
Mar 11, 2026
BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed in Hong Kong and the U.S., operating under both the Hong Kong Listing Rules and U.S. securities regulations. Its board features a chairman, a non-executive directo...
BeOne Medicines Opens New 2018 Employee Share Purchase Plan Offering Period
Mar 10, 2026
BeOne Medicines has launched a new six‑month offering period under its 2018 Employee Share Purchase Plan, running from March 2 to August 31, 2026, allowing eligible staff to buy shares or ADSs at a 15% discount to market. The plan, overseen ...
BeOne Medicines Grants New RSUs to 188 Employees Under Incentive Plan
Mar 6, 2026
BeOne Medicines has granted 21,197 restricted share units in the form of ADSs, representing 275,561 underlying shares or about 0.02% of its issued share capital, to 188 employees under its 2016 Share Option and Incentive Plan. The awards, which re...
BeOne Medicines Gains Clean Swiss Audit in Voluntary Disclosure
Feb 27, 2026
BeOne Medicines Ltd., a Swiss-incorporated biopharmaceutical company listed in Hong Kong, has provided an update on its governance and financial reporting, highlighting an internationally experienced board led by Chairman and Executive Director Jo...
BeOne Medicines Files 2025 Form 10-K, Underscoring Cross-Border Compliance
Feb 26, 2026
BeOne Medicines Ltd has announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The filing confirms the company’s status as a large accelerated...
BeOne Medicines posts 2025 results and issues cautious 2026 outlook
Feb 26, 2026
BeOne Medicines Ltd., a Switzerland-based biopharmaceutical group listed in Hong Kong, develops innovative drug candidates with a focus on hematology and other specialty therapies. The company is expanding globally and aligns its reporting with bo...
BeOne Medicines Sets Date for 2025 Results and Dual-Regime Reporting
Feb 11, 2026
BeOne Medicines Ltd. will release its fourth-quarter and full-year 2025 financial results, prepared under U.S. GAAP and SEC rules, on February 26, 2026, after Hong Kong trading hours, with the board set to review and approve the figures the same d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.